Anuh Pharma Ltd
₹ 76.0
0.16%
21 Aug
- close price
About
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]
Key Points
- Market Cap ₹ 762 Cr.
- Current Price ₹ 76.0
- High / Low ₹ 93.0 / 66.7
- Stock P/E 17.3
- Book Value ₹ 35.1
- Dividend Yield 1.97 %
- ROCE 14.9 %
- ROE 10.7 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 24.4%
Cons
- Company has a low return on equity of 13.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 | 779 | |
| 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 709 | 712 | |
| Operating Profit | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 62 | 67 |
| OPM % | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% | 9% |
| 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 4 | 5 | |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 11 | 11 |
| Profit before tax | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 54 | 60 |
| Tax % | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | 24% | |
| 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 41 | 44 | |
| EPS in Rs | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 4.10 | 4.41 |
| Dividend Payout % | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% | 37% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 10% |
| 3 Years: | 3% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | 4% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 14% |
| 3 Years: | 14% |
| Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| Reserves | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 302 |
| 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 | |
| 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 205 | |
| Total Liabilities | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
| 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 57 | |
| CWIP | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 84 |
| 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 416 | |
| Total Assets | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | -3 | |
| -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 | |
| -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 | |
| Net Cash Flow | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 | -12 |
| Free Cash Flow | 18 | 6 | 25 | -5 | -22 | 13 | -25 | 27 | 52 | 8 | 17 | -11 |
| CFO/OP | 96% | 78% | 149% | 49% | 56% | 232% | -20% | 80% | 130% | 42% | 78% | 16% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 | 113 |
| Inventory Days | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 | 90 |
| Days Payable | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 | 114 |
| Cash Conversion Cycle | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 | 89 |
| Working Capital Days | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 | 92 |
| ROCE % | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% | 15% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Installed Capacity MTPA |
|
||||||||||
| Export Revenue Share % |
|||||||||||
| Number of Countries (Export Reach) count |
|||||||||||
| Number of Customers count |
|||||||||||
| Total Production Volume MT |
|||||||||||
| Capacity Utilization % |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Investor Presentation
-
Announcement Under Regulation 30 - General Updates
- 66th AGM on 12 Aug 2026 approved director reappointments, cost auditor reappointment, JMD pay revisions, new MOA/AOA.
-
Announcement under Regulation 30 (LODR)-Change in Management
- At 66th AGM on 12 Aug 2026, shareholders approved director reappointments, cost auditor reappointment, and JMD remuneration revisions.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 66th AGM voting results approved; Rs.1.50 dividend, director reappointments, remuneration revisions, and MoA/AoA changes passed.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- Anuh Pharma held its 66th AGM on 12 Aug 2026; shareholders approved Rs.1.50 dividend and other resolutions.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Aug 2026TranscriptAI SummaryPPT
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Aug 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
Dec 2017TranscriptAI SummaryPPT
-
Feb 2016TranscriptAI SummaryPPT
-
Dec 2015TranscriptAI SummaryPPT
-
Sep 2015TranscriptAI SummaryPPT
-
Aug 2015TranscriptAI SummaryPPT
Part of SK Group of companies:[1]
The company is a bulk drug manufacturing company, and is part of the Rs. 8.5 billion SK Group. SK Group employs approximately 2,200 people across businesses including pharmaceutical formulations manufacturing, Trading, Distribution and Logistics (primarily for large MNC brands).